Cytek Biosciences Continues Momentum by Strengthening Executive Team
Company's Advanced Flow Cytometry Systems Being Embraced by Scientists, Clinicians Around the World
FREMONT, Calif., November 13, 2018 – Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, today announced that Steve Ziganti and Patrik S. Jeanmonod have joined the company's leadership team in the roles of vice president of worldwide sales and chief financial officer, respectively. Additionally, Jack Ball and Dr. Allen Poirson have been added to Cytek's board of directors.
From pharmaceutical and biotech companies to contract research organizations, the scientific community is embracing Cytek's Aurora and Northern Lights flow cytometry systems with open arms – and this success is driving the expansion of the company. Cytek is focused on making the advanced instrumentation that was once available to very few scientists accessible to more researchers. With Cytek's systems, more labs will have the ability to obtain deeper biological insights from a single sample – and accelerate their fields of research.
Ziganti brings years of achievement in the flow cytometry industry to his role as Cytek's vice president of worldwide sales. In his previous position as vice president of sales and service at BD Biosciences, Ziganti helped the company accelerate business growth. After retiring from BD for years, Ziganti was moved by Cytek's technology innovation to re-join the community. At Cytek, Ziganti will use his extensive experience to build Cytek's global sales team in order to reach scientists more rapidly. His focus will be on achieving the company's sales objectives, with particular attention paid to building its international sales infrastructure to support revenue growth.
As Cytek's CFO, Jeanmonod will head accounting and finance – including staff from both the U.S. and China – for the company. In this role, Jeanmonod will leverage his more than 20 years of experience to lead Cytek in transforming its accounting and inventory system toward a consolidated platform. He will also focus on managing the company's operating costs, which will allow Cytek to pass savings on to customers and accelerate collaborations. Before joining Cytek, Jeanmonod held executive positions in finance at various companies including three leading contract research organizations: Covance, Bridge Pharmaceuticals and Synteract. He is also currently a board member for Seal Biosciences Inc.
"The addition of Steve Ziganti and Patrik Jeanmonod, two of the finest executives in their fields, is a critical step to maintaining our strong growth," noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. "By continuing to extend and accelerate the company's reach and capabilities, we are well-positioned to deliver on our promise of making high-end, high-quality flow cytometry accessible to a larger number of scientists and clinicians."
Cytek's two new board members bring a wealth of experience in biotechnology development and business management to the company. A seasoned entrepreneur that sits on the board of multiple life science companies, Ball formerly served as the CEO of Amnis Corporation and CCO of Accuri Cytometers Inc. and Molecular Probes Inc. Dr. Poirson is a partner at Mighty Capital and previously served as CEO of Sony Biotechnology.
Please visit www.cytekbio.com for more information.
About Cytek Biosciences
Cytek Biosciences Inc. is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capability and a wide range of services to support researchers and clinicians. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. To learn more, visit www.cytekbio.com